Global Hydroxychloroquine Market Size study & Forecast, by Product Type (Tablet, Active Pharmaceutical Ingredients), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Store, Retail Pharmacy), by Disease (Malaria, Rheumatoid Arthr

Global Hydroxychloroquine Market Size study & Forecast, by Product Type (Tablet, Active Pharmaceutical Ingredients), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Store, Retail Pharmacy), by Disease (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, Coronavirus, Others) and Regional Analysis, 2023-2030

Global Hydroxychloroquine Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Hydroxychloroquine is an antimalarial medication used to treat uncomplicated cases of malaria and for chemoprophylaxis in specific regions. Hydroxychloroquine is often prescribed in combination with other antimalarial drugs for both prevention and treatment. In addition to its antimalarial properties, hydroxychloroquine has been used for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis and systemic lupus erythematosus (lupus). It is classified as a disease-modifying antirheumatic drug (DMARD) in these cases, where it helps to reduce inflammation and alleviate symptoms associated with autoimmune conditions. Hydroxychloroquine is being explored for potential therapeutic applications in various other conditions, including skin lesions and COVID-19, creating new market opportunities. The Hydroxychloroquine Market is expanding because of factors such as rising prevalence of malaria and increasing number of clinical trials.

The rise in incidences of target diseases is bolstering the market demand in the global market. Hydroxychloroquine is a leading treatment for malaria, a major health concern in many developing countries. The rising global population and increasing travel contribute to the sustained demand for this medication. According to WHO’s latest World malaria report, there were an estimated 241 million malaria cases and 627 000 malaria deaths worldwide in 2020. This represents about 14 million more cases in 2020 compared to 2019, and 69 000 more deaths. According to the ClinicalTrials.gov which currently lists 450,818 studies with locations in all 50 States and in 221 countries. As of March 2021, ClinicalTrials.gov receives about 4.5 million visitors monthly. The number of registered clinical trials has increased significantly in recent years. In addition, the rising penetration of generic drugs and advancement in formulation of anti-parasite drugs are acting as an opportunistic factors over the forecast period, . However, Side effects associated with hydroxychloroquine

The key regions considered for the Global Hydroxychloroquine Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the hydroxychloroquine market due to the region's significant product manufacturing capabilities and well-established healthcare infrastructure. The presence of robust research and development investments, coupled with a pool of skilled professionals, is poised to contribute further to the market's acceleration in this region. Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030. This growth is attributed to increased government awareness campaigns and the escalating healthcare costs in the region.

Major market player included in this report are:
Cadila Healthcare Limited
Hikma Pharmaceuticals PLC
Indian Pharmaceutical Combine Association Laboratories Ltd
Mylan N.V
Novartis AG
Pfizer Inc
Sanofi S.A.
Taj Pharma Group
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Limited

Recent Developments in the Market:
• In May 2, 2023, Icannex Healthcare, a company specializing in the development of medicinal cannabinoids and psychedelic therapies, initiated the Phase II trial for a combined therapy of cannabidiol (CBD) and hydroxychloroquine in the treatment of Rheumatoid Arthritis.
• In November 2020, Jubilant Pharma Limited, a company specializing in the production and distribution of radiopharmaceuticals, collaborated with Aavis Pharmaceuticals Inc, a U.S.-based pharmaceutical company. Together, they unveiled the introduction of Hydroxychloroquine tablets aimed at addressing Malaria, Rheumatoid Arthritis, and Lupus in the United States.
• In April 2020, Galenika, a pharmaceutical company headquartered in Serbia, and Zada Pharmaceuticals, a pharmaceutical company based in Bosnia, jointly declared the establishment of a manufacturing facility for chloroquine and hydroxychloroquine to be utilized in the treatment of patients with COVID-19.

Global Hydroxychloroquine Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Product Type, Distribution Channel, Disease, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type :
Tablet
Active Pharmaceutical Ingredients

By Distribution Channel :
Hospital Pharmacy
Online Pharmacy
Specialty Drug Store
Retail Pharmacy

By Disease:
Malaria
Rheumatoid Arthritis
Lupus Erythematosus
Coronavirus
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Cadila Healthcare Limited
Hikma Pharmaceuticals PLC
Indian Pharmaceutical Combine Association Laboratories Ltd
Mylan N.V
Novartis AG
Pfizer Inc
Sanofi S.A.
Taj Pharma Group
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.